Literature DB >> 29088344

Clinical long-term outcome of septal myectomy for obstructive hypertrophic cardiomyopathy in infants.

Julia Schleihauf1, Julie Cleuziou2, Jelena Pabst von Ohain2, Christian Meierhofer1, Heiko Stern1, Nerejda Shehu1, Naira Mkrtchyan1, Emanuel Kaltenecker1, Andreas Kühn1, Nicole Nagdyman1, Alfred Hager1, Heide Seidel3, Rüdiger Lange2, Peter Ewert1, Cordula M Wolf1.   

Abstract

OBJECTIVES: Surgical septal myectomy is performed to relieve left ventricular outflow tract narrowing in severe drug-refractory obstructive hypertrophic cardiomyopathy. The objective of this study was to assess the perioperative and long-term clinical outcome of this procedure performed during infancy.
METHODS: Clinical, transthoracic echocardiographic, electrocardiographic, 24-h Holter, cardiopulmonary exercise test and genetic data were extracted by medical record review. A subset of patients underwent additional prospective detailed clinical evaluation including cardiac magnetic resonance imaging with contrast.
RESULTS: Surgery was performed in 23 paediatric patients between 1978 and 2015 at the German Heart Centre Munich. Twelve patients had undergone surgery during infancy (≤ 1 year) (Group A), 11 between 1 and 18 years of age (Group B). The underlying genetic diagnosis was Noonan syndrome spectrum and non-syndromic hypertrophic cardiomyopathy. As compared to Group B, patients in Group A showed more concomitant cardiac procedures and received more homologous transfusions. One perioperative death occurred in Group A, and none in Group B. Two patients in Group A but no patient in Group B required redo septal myectomy. The long-term clinical outcome was similar between the 2 groups. One patient in Group B required cardioverter-defibrillator/pacemaker implantation for higher degree atrioventricular block and none in Group A. There was no evidence of differences in myocardial fibrosis between groups on long-term follow-up magnetic resonance imaging.
CONCLUSIONS: Surgical septal myectomy can be performed safely during infancy with favourable perioperative and long-term clinical outcome but with a trend towards a higher reoperation rate later in life.
© The Author 2017. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29088344     DOI: 10.1093/ejcts/ezx369

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

1.  Long-term outcomes of childhood onset Noonan compared to sarcomere hypertrophic cardiomyopathy.

Authors:  Emanuel Kaltenecker; Julia Schleihauf; Christian Meierhofer; Nerejda Shehu; Naira Mkrtchyan; Alfred Hager; Andreas Kühn; Julie Cleuziou; Karin Klingel; Heide Seidel; Martin Zenker; Peter Ewert; Gabriele Hessling; Cordula M Wolf
Journal:  Cardiovasc Diagn Ther       Date:  2019-10

2.  When is early septal myectomy in children with hypertrophic cardiomyopathy justified?

Authors:  Neha Bansal; Paul Barach; Shahnawaz M Amdani; Steven E Lipshultz
Journal:  Transl Pediatr       Date:  2018-10

3.  Endocardial Radiofrequency Ablation vs. Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy: A Systematic Review and Meta-Analysis.

Authors:  Tao Jiang; Bingyu Huang; Shengqi Huo; Lulu Monica Mageta; Junyi Guo; Jiagao Lv; Li Lin
Journal:  Front Surg       Date:  2022-04-26

4.  Subclinical Cardiac Dysfunction in Childhood Cancer Survivors on 10-Years Follow-Up Correlates With Cumulative Anthracycline Dose and Is Best Detected by Cardiopulmonary Exercise Testing, Circulating Serum Biomarker, Speckle Tracking Echocardiography, and Tissue Doppler Imaging.

Authors:  Cordula Maria Wolf; Barbara Reiner; Andreas Kühn; Alfred Hager; Jan Müller; Christian Meierhofer; Renate Oberhoffer; Peter Ewert; Irene Schmid; Jochen Weil
Journal:  Front Pediatr       Date:  2020-03-31       Impact factor: 3.418

Review 5.  Childhood Hypertrophic Cardiomyopathy: A Disease of the Cardiac Sarcomere.

Authors:  Gabrielle Norrish; Ella Field; Juan P Kaski
Journal:  Front Pediatr       Date:  2021-07-02       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.